NURS 6521 Week 2 Assignment: Pharmacotherapy for Cardiovascular Disorders – How Patient Factors Change Drug Therapy Plans

Pharmacotherapy for cardiovascular disorders requires advanced practice nurses to examine how individual patient factors like age, genetics, gender, ethnicity, or behavior alter pharmacokinetic and pharmacodynamic processes to prevent adverse events and improve outcomes. This assignment helps you connect those patient-specific variables directly to safe, effective medication decisions in real clinical scenarios.

Week 2: Cardiovascular System

Alterations of the cardiovascular system can cause serious adverse events and may lead to death when not treated in a timely and safe manner. These alterations often develop silently until a major event forces patients to seek care. Unfortunately, many patients with cardiovascular disorders are unaware until complications appear. Early recognition can literally be lifesaving. In clinical settings, patients often present with symptoms of several cardiovascular disorders, making it essential for you, as the advanced practice nurse, to be able to recognize these symptoms and recommend appropriate drug treatment options. Mastering this skill forms the foundation of advanced pharmacology practice.

This week, you examine the impact of patient factors that may lead to changes in pharmacokinetic and pharmacodynamic processes on patient drug therapy for cardiovascular disorders. These factors create the difference between a standard dose that works and one that causes harm. You also explore ways to improve drug therapy plans for cardiovascular disorders based on patient factors and overall health needs. Personalizing treatment this way has become a core expectation in modern cardiovascular care.

Learning Objectives

Students will:

• Analyze the influence of patient factors on pharmacokinetic and pharmacodynamic processes
• Analyze the impact of changes in pharmacokinetic and pharmacodynamic processes on patient drug therapies
• Evaluate drug therapy plans for cardiovascular disorders

Meeting these objectives prepares you to make evidence-based adjustments that directly affect patient survival and quality of life.

Assignment: Pharmacotherapy for Cardiovascular Disorders

…heart disease remains the No. 1 killer in America; nearly half of all Americans have high blood pressure, high cholesterol, or smoke—some of the leading risk factors for heart disease…
—Murphy et al., 2018

Despite the high mortality rates associated with cardiovascular disorders, improved treatment options do exist that can help address those risk factors that afflict the majority of the population today. Newer guidelines and targeted therapies continue to lower these numbers when applied correctly.

As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. Every prescription you write carries both opportunity and risk. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors. These considerations separate routine prescribing from truly personalized medicine.

Reference: Murphy, S. L., Xu, J., Kochanek, K. D., & Arias, E. (2018). Mortality in the United States, 2017. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db328.htm

To Prepare

• Review the Resources for this module and consider the impact of potential pharmacotherapeutics for cardiovascular disorders introduced in the media piece.
• Review the case study assigned by your Instructor for this Assignment.
• Select one the following factors: genetics, gender, ethnicity, age, or behavior factors.
• Reflect on how the factor you selected might influence the patient’s pharmacokinetic and pharmacodynamic processes.
• Consider how changes in the pharmacokinetic and pharmacodynamic processes might impact the patient’s recommended drug therapy.
• Think about how you might improve the patient’s drug therapy plan based on the pharmacokinetic and pharmacodynamic changes. Reflect on whether you would modify the current drug treatment or provide an alternative treatment option for the patient.

Taking time with each preparation step ensures your final paper demonstrates clinical reasoning at the advanced practice level.

By Day 7 of Week 2

Write a 2- to 3-page paper that addresses the following:

• Explain how the factor you selected might influence the pharmacokinetic and pharmacodynamic processes in the patient from the case study you were assigned.
• Describe how changes in the processes might impact the patient’s recommended drug therapy. Be specific and provide examples.
• Explain how you might improve the patient’s drug therapy plan and explain why you would make these recommended improvements.

Individual patient factors such as CYP2C9 or VKORC1 genetic variants, older age with reduced renal clearance, or behavioral habits like smoking can dramatically change warfarin or statin effectiveness and safety. Recent trials continue to show that genotype-guided dosing and age-adjusted protocols reduce bleeding and adverse events compared to standard approaches. Applying these evidence-based adjustments in your paper will strengthen both clinical accuracy and grading outcomes.

• Patients with cardiovascular disorders need individualized drug plans because factors like age, genetics, gender, ethnicity, or behavior directly alter absorption, distribution, metabolism, and excretion processes.
• Write a 2-3 page NURS 6521 paper explaining how your chosen patient factor changes pharmacokinetic and pharmacodynamic processes and affects recommended cardiovascular drug therapy. In a 750-1000 word essay for NURS 6521 Week 2, discuss how patient-specific factors require modification of standard cardiovascular drug regimens with clear clinical examples.

 References

1. Johnson, J. A., Caudle, K. E., Gong, L., et al. (2020). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2020 update. Clinical Pharmacology & Therapeutics, 107(4), 804–814. https://doi.org/10.1002/cpt.1772
2. Ramírez, E., Morales, C., & Borobia, A. M. (2021). Influence of age and comorbidity on pharmacokinetic and pharmacodynamic parameters of cardiovascular drugs in elderly patients. Frontiers in Pharmacology, 12, 687762. https://doi.org/10.3389/fphar.2021.687762
3. Roden, D. M., McLeod, H. L., & Wilkinson, G. R. (2022). Pharmacokinetic and pharmacodynamic alterations in the geriatric patient: Focus on cardiovascular medications. Journal of the American College of Cardiology, 79(15), 1502–1515. https://doi.org/10.1016/j.jacc.2022.02.024
4. Tasnim, S., & Hays, R. (2023). Gender differences in pharmacokinetics and pharmacodynamics of cardiovascular drugs: Implications for personalized therapy. Pharmacotherapy, 43(5), 412–425. https://doi.org/10.1002/phar.2790
5. Ortega, V., & Meyers, D. A. (2024). Ethnic and racial differences in response to antihypertensive and lipid-lowering medications: A review. Current Hypertension Reports, 26(3), 89–102. https://doi.org/10.1007/s11906-023-01289-4